<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="clt270038" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Allergy</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Allergy</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7022</journal-id><journal-id journal-id-type="publisher-id">CLT2</journal-id><journal-title-group><journal-title>Clinical and Translational Allergy</journal-title></journal-title-group><issn pub-type="epub">2045-7022</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891034</article-id><article-id pub-id-type="pmc">PMC11785471</article-id><article-id pub-id-type="doi">10.1002/clt2.70038</article-id><article-id pub-id-type="publisher-id">CLT270038</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Development of the symptomatic dermographism quality of life questionnaire</article-title></title-group><contrib-group><contrib id="clt270038-cr-0001" contrib-type="author" corresp="yes"><name><surname>Mu&#x000f1;oz</surname><given-names>Melba</given-names></name><xref rid="clt270038-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="clt270038-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>melba.munoz-roldan@charite.de</email></address></contrib><contrib id="clt270038-cr-0002" contrib-type="author"><name><surname>Schoepke</surname><given-names>Nicole</given-names></name><xref rid="clt270038-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="clt270038-cr-0003" contrib-type="author"><name><surname>Altrichter</surname><given-names>Sabine</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9955-385X</contrib-id><xref rid="clt270038-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="clt270038-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="clt270038-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="clt270038-cr-0004" contrib-type="author"><name><surname>Staubach</surname><given-names>Petra</given-names></name><xref rid="clt270038-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="clt270038-cr-0005" contrib-type="author"><name><surname>Geppert&#x02010;Steidl</surname><given-names>Clara</given-names></name><xref rid="clt270038-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="clt270038-cr-0006" contrib-type="author"><name><surname>Durner</surname><given-names>Leslie</given-names></name><xref rid="clt270038-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="clt270038-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="clt270038-cr-0007" contrib-type="author"><name><surname>Bernstein</surname><given-names>Jonathan A.</given-names></name><xref rid="clt270038-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="clt270038-cr-0008" contrib-type="author"><name><surname>Maurer</surname><given-names>Marcus</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4121-481X</contrib-id><xref rid="clt270038-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="clt270038-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="clt270038-cr-0009" contrib-type="author"><name><surname>Weller</surname><given-names>Karsten</given-names></name><xref rid="clt270038-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="clt270038-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="clt270038-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Institute of Allergology</named-content>
<institution>Charit&#x000e9; &#x02010; Universit&#x000e4;tsmedizin Berlin</institution>
<institution>Corporate Member of Freie Universit&#x000e4;t Berlin</institution>
<institution>and Humboldt&#x02010;Universit&#x000e4;t zu Berlin</institution>
<city>Mainz</city>
<country country="DE">Germany</country>
</aff><aff id="clt270038-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Immunology and Allergology</named-content>
<institution>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP</institution>
<city>Mainz</city>
<country country="DE">Germany</country>
</aff><aff id="clt270038-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Dermatology and Venerology</named-content>
<institution>Kepler University Hospital</institution>
<city>Linz</city>
<country country="AT">Austria</country>
</aff><aff id="clt270038-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>Johannes Gutenberg University</institution>
<city>Mainz</city>
<country country="DE">Germany</country>
</aff><aff id="clt270038-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Division of Immunology and Allergy</named-content>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>University of Cincinnati College of Medicine</institution>
<city>Cincinnati</city>
<named-content content-type="country-part">Ohio</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Melba Mu&#x000f1;oz, Institute of Allergology, Charit&#x000e9; &#x02010; Universit&#x000e4;tsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany.<break/>
Email: <email>melba.munoz-roldan@charite.de</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>15</volume><issue seq="20">2</issue><issue-id pub-id-type="doi">10.1002/clt2.v15.2</issue-id><elocation-id>e70038</elocation-id><history>
<date date-type="rev-recd"><day>27</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>28</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). Clinical and Translational Allergy published by John Wiley &#x00026; Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CLT2-15-e70038.pdf"/><abstract><title>Abstract</title><sec id="clt270038-sec-0001"><title>Background</title><p>Symptomatic Dermographism (SD), also known as &#x0201c;urticaria factitia&#x0201d;, is the most common subtype of chronic inducible urticaria. Affected patients develop itch and strip&#x02010;shaped wheals that usually last for 30&#x000a0;min after minor stroking, rubbing, or scratching of the skin. The quality of life (QoL) of patients with SD is often strongly affected. However, a QoL instrument to properly assess this impairment is not yet available.</p></sec><sec id="clt270038-sec-0002"><title>Objective</title><p>The aim of this study was to develop the first disease&#x02010;specific patient reported outcome measure|patient reported outcome measures (PROM) to evaluate QoL impairment in SD patients, the Symptomatic Dermographism Quality of Life Questionnaire (SD&#x02010;QoL).</p></sec><sec id="clt270038-sec-0003"><title>Methods</title><p>SD&#x02010;QoL was developed following current guidelines for PROM development. We first generated a hypothetical conceptional framework of the SD&#x02010;QoL, followed by an item generation and an item selection/reduction phase.</p></sec><sec id="clt270038-sec-0004"><title>Results</title><p>During the item generation phase, 69 potential items of the SD&#x02010;QoL were generated by applying a combined approach consisting of literature review, expert input as well as semi&#x02010;structured interviews with affected patients. During the item selection phase, we reduced this long list of items to a final 13&#x02010;item set by means of impact analysis, inter&#x02010;item correlation, and additional criteria for item reduction, including an expert review for content (face) validity. Finally, a US&#x02010;American&#x02010;English version of the SD&#x02010;QoL was developed using a structured translation process.</p></sec><sec id="clt270038-sec-0005"><title>Conclusions and Clinical Relevance</title><p>The SD&#x02010;QoL is the first disease&#x02010;specific&#x02010;QoL instrument for SD with a recall period of 7&#x000a0;days that allows the assessment of QoL in SD patients. A subsequent validation study will determine its validity and reliability.</p></sec></abstract><kwd-group><kwd id="clt270038-kwd-0001">development</kwd><kwd id="clt270038-kwd-0002">patient&#x02010;reported outcome</kwd><kwd id="clt270038-kwd-0003">quality of life</kwd><kwd id="clt270038-kwd-0004">symptomatic dermographism</kwd><kwd id="clt270038-kwd-0005">urticaria</kwd></kwd-group><counts><fig-count count="4"/><table-count count="4"/><page-count count="14"/><word-count count="6680"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:31.01.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="clt270038-cit-0025">
<string-name>
<surname>Mu&#x000f1;oz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schoepke</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Altrichter</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Development of the symptomatic dermographism quality of life questionnaire</article-title>. <source>Clin Transl Allergy</source>. <year>2025</year>;<elocation-id>e70038</elocation-id>. <pub-id pub-id-type="doi">10.1002/clt2.70038</pub-id>
</mixed-citation>
</p></notes></front><body id="clt270038-body-0001"><sec id="clt270038-sec-0010"><label>1</label><title>INTRODUCTION</title><p>Symptomatic dermographism (SD) also known as urticaria factitia or dermographic urticaria is the most common form of chronic inducible urticaria (CIndU).<xref rid="clt270038-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> It affects 1%&#x02013;5% of the general population and usually persists for many years before spontaneous remission.<xref rid="clt270038-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="clt270038-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> In some cases, it has also been reported to be a familial disease.<xref rid="clt270038-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="clt270038-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>SD is characterized by the recurrent appearance of itchy linear&#x02010;shaped wheals after skin exposure to shear forces, for example, light stroking, scratching, or rubbing that can last for 30&#x000a0;min to 1&#x000a0;h.<xref rid="clt270038-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="clt270038-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> While a defining feature of SD is the appearance of wheals after scratching, most patients report that the scratching itself is a consequence of a generalized itch, which occurs spontaneously. Therefore, itch and the predisposition of the patient's skin to react with wheals after scratching or applying other shear forces are the main components of SD. These two components are not only important for the pathophysiological understanding of SD but also important for understanding and assessing the patient's disease burden.</p><p>Mast cell activation through autoreactive IgE antibodies with the subsequent release of histamine and other proinflammatory mediators are key pathophysiological events in all forms of urticaria.<xref rid="clt270038-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="clt270038-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="clt270038-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="clt270038-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="clt270038-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="clt270038-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> A recent study showed that mast cells are essential for the development of SD since a single intravenous treatment with an anti&#x02010;KIT monoclonal antibody (mAb) barzolvolimab, depleted skin mast cells and completely abolished SD symptoms.<xref rid="clt270038-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><p>Furthermore, the development of wheals in response to skin friction that characterizes SD was shown to be transferable by serum transfer experiments.<xref rid="clt270038-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="clt270038-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> H<sub>1</sub>&#x02010;anthistamines are the first&#x02010;line and only licensed treatment option for SD. However, H<sub>1</sub>&#x02010;anthistamines often do not control SD symptoms, even when given continuously up to four times the recommended daily dose as recommended by the current guidelines.<xref rid="clt270038-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> In some cases, skin moisturizers can help to reduce itch and alleviate the symptoms. Studies aiming a evaluating novel treatment options are urgently needed, but they are hampered by the lack of suitable outcome measures. Existing instruments in the field of urticaria, such as the Chronic Urticaria quality of life (QoL) Questionnaire (CU&#x02010;Q<sub>2</sub>oL),<xref rid="clt270038-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> primarily developed for chronic spontaneous urticaria (CSU), do not consider the inducibility of signs and symptoms of CIndUs. Many SD patients report significant impairment of their QoL since their daily activities are affected by their symptoms.<xref rid="clt270038-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="clt270038-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Therefore, an instrument to assess QoL in SD patients is crucial to objectively evaluate the burden of the disease and response to therapy. The first disease specific health&#x02010;related quality of life (HRQoL) questionnaire for an inducible urticaria, the Cholinergic Urticaria QoL Questionnaire, is published,<xref rid="clt270038-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> but disease&#x02010;specific questionnaires for all other CIndU subforms, including SD, are still not available. Generic HRQoL instruments might be otherwise applied to evaluate the impact of SD on the QoL of SD patients. However, these instruments are non&#x02010;specific and usually not sensitive enough to capture real disease burden, which is critical for patient assessment in clinical studies and in routine patient care.</p><p>To address this medical unmet need, we developed an SD&#x02010;specific patient reported outcome measure|patient reported outcome measures (PROM) that assesses QoL impairment in SD patients, called the symptomatic dermographism quality of Life Questionnaire (SD&#x02010;QoL).</p></sec><sec id="clt270038-sec-0020"><label>2</label><title>METHODS</title><sec id="clt270038-sec-0030"><label>2.1</label><title>Patient sample and data acquisition</title><p>For the development of the SD&#x02010;QoL, &#x02265;18&#x02010;year&#x02010;old patients were recruited at the outpatient clinic of the Department of Dermatology and Allergy, Charit&#x000e9; &#x02010; Universit&#x000e4;tsmedizin Berlin and at the Department of Dermatology of the University Medical Center in Mainz, Germany. Our study was approved by the local ethics committee and all patients provided written informed consent before participating in the study. This work consisted of three main phases: 1) assembly of an expert working group and generation of a conceptional framework of the SD&#x02010;QoL, 2) an item generation phase, and 3) an item reduction/selection phase. The development method was based on current recommendations for PROM<xref rid="clt270038-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> as well as according to the Food and Drug Administration (FDA) guidance,<xref rid="clt270038-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> European Medicines Agency recommendations<xref rid="clt270038-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> and the recommendations of GA<sup>2</sup>LEN taskforce position paper.<xref rid="clt270038-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p></sec><sec id="clt270038-sec-0040"><label>2.2</label><title>Expert group and conceptional framework</title><p>In a first step, an expert group was convened to take over several tasks: 1) to generate the conceptual framework of the SD&#x02010;QoL, 2) to provide input during the item generation phase, 3) to guide the item reduction process, 4) to review the item selection for content (face) validity, and 5) to define criterion measures (anchor instruments) to be applied during the validation study of the SD&#x02010;QoL. The expert group consisted of experts in the field of SD patient care in the field of clinical trials, and in the field of PROM development.</p></sec><sec id="clt270038-sec-0050"><label>2.3</label><title>Item generation</title><p>In a second step, after the conceptional framework was outlined, potential questions (items) for the SD&#x02010;QoL were developed (unselected item long list). To this end, we performed exploratory semi&#x02010;structured interviews with SD patients (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;10). The interviews asked about SD&#x02010;specific symptoms, their influence on daily activities, body care, physical and emotional well&#x02010;being as well as on social interactions. In addition, we performed a literature search on SD symptoms and their impact on affected patients as well as PROMs that have already been used in the field of SD. The expert group was asked to provide input on topics that needed to be addressed during the development of the SD&#x02010;QoL for example, finding the appropriate wording to define the items.</p></sec><sec id="clt270038-sec-0060"><label>2.4</label><title>Item reduction and selection</title><p>In the third step, an item reduction was performed to delete items of low importance for the patients, to eliminate redundant items from the long list, and to ensure a good balance of topics regarding the content validity of the SD&#x02010;QoL and the corresponding burden. For the reduction phase, impact analysis and inter&#x02010;item&#x02010;correlation were performed. Moreover, the expert group defined the additional criteria for item selection and reviewed the selected items to determine the overall final item set.</p></sec><sec id="clt270038-sec-0070"><label>2.5</label><title>Impact analysis</title><p>For the impact analysis and the inter&#x02010;item correlation, all generated items (unselected item long list) were handed out to 58 SD patients. All patients were asked to complete all items as well as to rate the importance of each item on a scale from 0 (not important) to 4 (very important). In addition, patients rated the content of each item in terms of its relevance to their SD symptoms within the last 12&#x000a0;months (answer option &#x0201c;yes&#x0201d; or &#x0201c;no&#x0201d;). Each item's &#x0201c;frequency&#x0201d; was then calculated as the percentage of patients who reported the relevance of the indicated item divided by 100. Subsequently, the impact scores were calculated by multiplying the mean of the &#x0201c;importance&#x0201d; by the &#x0201c;frequency&#x0201d; of each item.</p></sec><sec id="clt270038-sec-0080"><label>2.6</label><title>Inter&#x02010;item correlation</title><p>An inter&#x02010;item correlation analysis was performed to identify redundant items by using Spearman rank correlation of all items selected during the impact analysis. The interpretation of the Spearman rank correlation coefficient was as follows: 0.5&#x02013;0.699 good correlation, 0.7&#x02013;0.899 strong correlation and&#x000a0;&#x02265;&#x000a0;0.9 very strong correlation, which indicates redundancy of the respective items.</p></sec><sec id="clt270038-sec-0090"><label>2.7</label><title>Additional criteria for the deletion of items</title><p>The most important criteria for the deletion of items were a low impact score in the impact analysis. However, additional criteria suggesting an item deletion were 1) high floor and ceiling values (&#x02265;30%) because this indicates a rather poor variability of responses, 2) a considerable number of missing responses (&#x0003e;5%), indicating a poor relevance or items that were difficult to understand, 3) strong (0.7&#x02013;0.899) and very strong inter&#x02010;item&#x02010;correlation (&#x02265;0.9 correlation), reflecting redundancy. Moreover, the expert group deleted some items in favor of similar items with better properties and/or better content (face) validity.</p></sec><sec id="clt270038-sec-0100"><label>2.8</label><title>Final formatting and cognitive debriefing of the symptomatic dermographism quality of life questionnaire</title><p>After the item reduction phase was completed, an instruction section (explaining how to complete this tool) was added to the final SD&#x02010;QoL. Subsequently, the final SD&#x02010;QoL was subjected to a cognitive debriefing with 10 SD patients to confirm the comprehensiveness and comprehensibility of the instruction section, all items and answer options.</p></sec><sec id="clt270038-sec-0110"><label>2.9</label><title>Development of an American&#x02010;English version</title><p>After the final formatting of the SD&#x02010;QoL, a US American&#x02010;English version was developed. To this end, the German version of the SD&#x02010;QoL was translated to American&#x02010;English by two independent native US American&#x02010;English speakers that were bilingual in the source language German. Both forward translations were then reviewed, reconciled, and edited by a US American&#x02010;English native speaker and urticaria expert. Subsequently, a back&#x02010;translation was performed by a German native speaker, bilingual in American&#x02010;English, and this back&#x02010;translation was compared to the German source. After the US American&#x02010;English translation was regarded equivalent to the German version, it underwent cognitive debriefing with five US American&#x02010;English native speaking SD patients to test its comprehensiveness and comprehensibility.</p></sec><sec id="clt270038-sec-0120"><label>2.10</label><title>Statistical analyses</title><p>All statistical analyses were performed using Statistical Package for Social Sciences (SPSS) (IBM SPSS Statistics Version 28.0.1; IBM Corporation).</p></sec></sec><sec id="clt270038-sec-0130"><label>3</label><title>RESULTS</title><sec id="clt270038-sec-0140"><label>3.1</label><title>Conceptional framework</title><p>The conceptional framework of the SD&#x02010;QoL was developed by the expert group. The target group of the SD&#x02010;QoL was defined as all adult patients with SD. The major functions of the SD&#x02010;QoL were specified as 1) the determination of the overall SD&#x02010;related QoL impairment as well as 2) the assessment of the pattern of impairment. Accordingly, the SD&#x02010;QoL was intended to have a total score (application option as an index instrument) as well as different QoL dimension scores (application option as a profile measure). An additional purpose of the SD&#x02010;QoL was defined to be the determination of changes of SD&#x02010;related QoL over time, for example, changes occurring during the change of treatments. The way of assessment was decided to be retrospective so that results are available instantly after administration and the SD&#x02010;QoL was intended as a self&#x02010;administered questionnaire (either on paper or electronically). Finally, it was decided that the SD&#x02010;QoL should contain content on the physical, social and emotional burden of SD as well as on the &#x0201c;functioning&#x0201d; of the patients in daily life.</p></sec></sec><sec id="clt270038-sec-0150"><label>4</label><title>SYMPTOMATIC DERMOGRAPHISM QUALITY OF LIFE QUESTIONNAIRE QUESTIONNAIRE DEVELOPMENT</title><sec id="clt270038-sec-0160"><label>4.1</label><title>Item generation</title><p>The combined approach of patient input, literature search, and expert input resulted in an unselected long list of 69 potential SD&#x02010;QoL items (Table&#x000a0;<xref rid="clt270038-tbl-0001" ref-type="table">1</xref>). The semi&#x02010;structured interviews were performed with 10 SD patients (40% males and 60% females) with a median age of 35.5&#x000a0;years (33&#x02013;40&#x000a0;years) and a median disease duration of 2&#x000a0;years (Table&#x000a0;<xref rid="clt270038-tbl-0002" ref-type="table">2</xref>). Thirty&#x02010;four percent of patients in our study reported having another minor urticaria form. From these, 27% patients reported a CSU and 10% reported another CIndU subtype. Although, CSU and SD symptoms can be similar, the characteristic induction of strip&#x02010;shaped wheals after stroking of the skin in response to itch allows us to determine the impact of QoL due to SD&#x02010;specific symptoms. All SD patients referred that itch was the most frequent and the most relevant symptom and all patients indicated that they had an impaired QoL due to their disease. The mean urticaria control test (UCT) of our SD patients was nine points and the mean Dermatological life quality index (DLQI) was six points, which corresponds to poorly controlled disease and moderate impact on the QoL of these patients, respectively. Furthermore, 66% of patients in this study reported mild to moderate itch and 50% reported mild or no occurrence of hives. Therefore, our sample size represents all severity levels, from mild to moderate to severe SD cases. Based on the patient interviews and expert input, the item recall period was defined as 7&#x000a0;days. The item responses were configured as five&#x02010;point verbal rating scales. The answer options were designed to be clearly understood and to have similar intervals between the five options. Moreover, five response options were regarded as suitable to not bias the responses toward one direction and have also been proven to be a suitable approach in many other PROMs. The score range of all answer options was defined to be 0&#x02013;4 points for all items to ensure equally weighted item scores, with low scores indicating responses associated with a mild QoL impairment and high item scores indicating responses associated with severe QoL impairment.</p><table-wrap position="float" id="clt270038-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Impact analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="left" valign="bottom" rowspan="1" colspan="1">Item</th><th align="left" valign="bottom" rowspan="1" colspan="1">Importance</th><th align="left" valign="bottom" rowspan="1" colspan="1">Frequency</th><th align="left" valign="bottom" rowspan="1" colspan="1">Impact score</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_1</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Itch (intensity)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3.05</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.95</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.89</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_2</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Wheals (intensity)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.76</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.91</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.51</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_3</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Skin redness (intensity)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.79</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.95</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.64</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_4</td><td align="left" valign="top" rowspan="1" colspan="1">Skin pain (intensity)</td><td align="left" valign="top" rowspan="1" colspan="1">1.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_5</td><td align="left" valign="top" rowspan="1" colspan="1">Skin burning (intensity)</td><td align="left" valign="top" rowspan="1" colspan="1">1.98</td><td align="left" valign="top" rowspan="1" colspan="1">0.65</td><td align="left" valign="top" rowspan="1" colspan="1">1.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_6</td><td align="left" valign="top" rowspan="1" colspan="1">Skin sensation of heat (intensity)</td><td align="left" valign="top" rowspan="1" colspan="1">1.81</td><td align="left" valign="top" rowspan="1" colspan="1">0.65</td><td align="left" valign="top" rowspan="1" colspan="1">1.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Itch (frequency)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3.00</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.98</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.95</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_8</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Wheals (frequency)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.60</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.86</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.24</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_9</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Skin redness (frequency)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.68</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.91</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.44</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_10</td><td align="left" valign="top" rowspan="1" colspan="1">Skin pain (frequency)</td><td align="left" valign="top" rowspan="1" colspan="1">1.61</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_11</td><td align="left" valign="top" rowspan="1" colspan="1">Skin burning (frequency)</td><td align="left" valign="top" rowspan="1" colspan="1">1.96</td><td align="left" valign="top" rowspan="1" colspan="1">0.66</td><td align="left" valign="top" rowspan="1" colspan="1">1.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_12</td><td align="left" valign="top" rowspan="1" colspan="1">Skin sensation of heat (frequency)</td><td align="left" valign="top" rowspan="1" colspan="1">2.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.68</td><td align="left" valign="top" rowspan="1" colspan="1">1.37</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_13</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation at school/study/work</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.57</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.80</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.06</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_14</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on family life</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.47</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.78</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.92</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_15</td><td align="left" valign="top" rowspan="1" colspan="1">Limitation on housework</td><td align="left" valign="top" rowspan="1" colspan="1">1.79</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td><td align="left" valign="top" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_16</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on leisure time</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.26</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.69</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.56</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_17</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on partnership</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.40</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.72</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.73</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_18</td><td align="left" valign="top" rowspan="1" colspan="1">Limitation on social life</td><td align="left" valign="top" rowspan="1" colspan="1">2.26</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">1.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_19</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on sexual life</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.56</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.63</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.62</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_20</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on physical activities</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.29</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.67</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.54</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_21</td><td align="left" valign="top" rowspan="1" colspan="1">Limitation on sports</td><td align="left" valign="top" rowspan="1" colspan="1">2.12</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">1.26</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_22</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on body care</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.40</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.71</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.70</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_23</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on choice of clothes</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.44</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.62</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.52</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_24</td><td align="left" valign="top" rowspan="1" colspan="1">Limitation on choice of cosmetics</td><td align="left" valign="top" rowspan="1" colspan="1">2.14</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">1.33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_25</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Impairment of sleep</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.19</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.70</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.54</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_26</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Unable to fall asleep</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.33</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.67</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.55</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_27</td><td align="left" valign="top" rowspan="1" colspan="1">Unable to sleep through the night</td><td align="left" valign="top" rowspan="1" colspan="1">2.19</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">1.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_28</td><td align="left" valign="top" rowspan="1" colspan="1">Waking up many times</td><td align="left" valign="top" rowspan="1" colspan="1">2.22</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">1.33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_29</td><td align="left" valign="top" rowspan="1" colspan="1">Tired during the day</td><td align="left" valign="top" rowspan="1" colspan="1">2.07</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">1.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_30</td><td align="left" valign="top" rowspan="1" colspan="1">Difficulty to concentrate</td><td align="left" valign="top" rowspan="1" colspan="1">2.22</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td><td align="left" valign="top" rowspan="1" colspan="1">1.40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_31</td><td align="left" valign="top" rowspan="1" colspan="1">Mental performance</td><td align="left" valign="top" rowspan="1" colspan="1">2.14</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">1.13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_32</td><td align="left" valign="top" rowspan="1" colspan="1">Hiding skin lesions from others</td><td align="left" valign="top" rowspan="1" colspan="1">2.07</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">1.18</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_33</td><td align="left" valign="top" rowspan="1" colspan="1">Avoiding public places</td><td align="left" valign="top" rowspan="1" colspan="1">1.61</td><td align="left" valign="top" rowspan="1" colspan="1">0.40</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_34</td><td align="left" valign="top" rowspan="1" colspan="1">Appearance</td><td align="left" valign="top" rowspan="1" colspan="1">2.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td><td align="left" valign="top" rowspan="1" colspan="1">1.45</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_35</td><td align="left" valign="top" rowspan="1" colspan="1">Contact to others</td><td align="left" valign="top" rowspan="1" colspan="1">2.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_36</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling ashamed</td><td align="left" valign="top" rowspan="1" colspan="1">2.12</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">1.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_37</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling embarrased</td><td align="left" valign="top" rowspan="1" colspan="1">2.12</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">1.23</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_38</td><td align="left" valign="top" rowspan="1" colspan="1">Fear from the reaction of other people</td><td align="left" valign="top" rowspan="1" colspan="1">1.95</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_39</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling of losing control of life</td><td align="left" valign="top" rowspan="1" colspan="1">1.88</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_40</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Feeling of no control over urticaria</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.53</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.67</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.69</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_41</td><td align="left" valign="top" rowspan="1" colspan="1">Mood swings</td><td align="left" valign="top" rowspan="1" colspan="1">2.18</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">1.24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_42</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Fear that disease might worsen</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.61</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.75</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.97</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_43</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Scratching frequency</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3.18</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.93</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.96</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_44</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling of uncertainty</td><td align="left" valign="top" rowspan="1" colspan="1">2.14</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td><td align="left" valign="top" rowspan="1" colspan="1">1.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_45</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Anxious about drug side &#x02010; effects</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.34</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.71</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.67</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_46</td><td align="left" valign="top" rowspan="1" colspan="1">Less achieved than aimed</td><td align="left" valign="top" rowspan="1" colspan="1">1.79</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_47</td><td align="left" valign="top" rowspan="1" colspan="1">Preference to stay at home</td><td align="left" valign="top" rowspan="1" colspan="1">1.74</td><td align="left" valign="top" rowspan="1" colspan="1">0.39</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_48</td><td align="left" valign="top" rowspan="1" colspan="1">Limited overall performance</td><td align="left" valign="top" rowspan="1" colspan="1">2.07</td><td align="left" valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1">1.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_49</td><td align="left" valign="top" rowspan="1" colspan="1">Limitations on going out</td><td align="left" valign="top" rowspan="1" colspan="1">1.78</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td><td align="left" valign="top" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_50</td><td align="left" valign="top" rowspan="1" colspan="1">Having drug side &#x02010; effects</td><td align="left" valign="top" rowspan="1" colspan="1">2.31</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">1.39</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_51</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Emotionally burdened</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.67</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.72</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.92</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_52</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling nervous</td><td align="left" valign="top" rowspan="1" colspan="1">2.14</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">1.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_53</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling uneasy</td><td align="left" valign="top" rowspan="1" colspan="1">2.23</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">1.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_54</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling afraid</td><td align="left" valign="top" rowspan="1" colspan="1">1.79</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_55</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Feeling helpless</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.41</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.66</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.58</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_56</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Feeling at the mercy of the disease</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.33</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.67</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.57</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_57</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling powerless</td><td align="left" valign="top" rowspan="1" colspan="1">2.11</td><td align="left" valign="top" rowspan="1" colspan="1">0.68</td><td align="left" valign="top" rowspan="1" colspan="1">1.44</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_58</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Feeling frustrated</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.53</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.74</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.86</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_59</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling depressed</td><td align="left" valign="top" rowspan="1" colspan="1">2.19</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">1.25</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_60</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling discouraged</td><td align="left" valign="top" rowspan="1" colspan="1">2.04</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">1.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_61</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling downhearted</td><td align="left" valign="top" rowspan="1" colspan="1">2.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">1.06</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_62</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling sad</td><td align="left" valign="top" rowspan="1" colspan="1">2.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">1.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_63</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling tired</td><td align="left" valign="top" rowspan="1" colspan="1">2.14</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td><td align="left" valign="top" rowspan="1" colspan="1">1.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_64</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Feeling annoyed</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.67</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.81</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.15</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_65</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Feeling upset</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2.28</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.67</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.52</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_66</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling angry</td><td align="left" valign="top" rowspan="1" colspan="1">1.91</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_67</td><td align="left" valign="top" rowspan="1" colspan="1">Feelings aggressive</td><td align="left" valign="top" rowspan="1" colspan="1">1.80</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td><td align="left" valign="top" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_68</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling stressed</td><td align="left" valign="top" rowspan="1" colspan="1">2.32</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td><td align="left" valign="top" rowspan="1" colspan="1">1.46</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_69</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling exhausted</td><td align="left" valign="top" rowspan="1" colspan="1">2.10</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">1.20</td></tr></tbody></table><table-wrap-foot id="clt270038-ntgp-0001"><fn id="clt270038-note-0001"><p>
<italic toggle="yes">Note</italic>: A combined approach of patient input, literature search, and expert input resulted in an unselected long list of 69 potential SD&#x02010;QoL items. An impact analysis was performed to select relevant and important items for the final SD&#x02010;QoL. Items with an impact score of &#x02265; 1.5 points are depicted in bold.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="clt270038-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Demographic characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">SD patients</th><th align="left" valign="bottom" rowspan="1" colspan="1">Semi&#x02010;structured interviews</th><th align="left" valign="bottom" rowspan="1" colspan="1">Item selection and reduction phase</th><th align="left" valign="bottom" rowspan="1" colspan="1">CD German</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#x000a0;=&#x000a0;10</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#x000a0;=&#x000a0;58</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#x000a0;=&#x000a0;10</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Male <italic toggle="yes">N</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (40%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (21%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (40%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female <italic toggle="yes">N</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (60%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">46 (79%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (60%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age in years (median, IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">3.7 (33&#x02013;40)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">43 (31&#x02013;50.5)</td><td align="left" valign="top" rowspan="1" colspan="1">44.7 (30&#x02013;61.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">18&#x02013;30&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (20%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (19%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (30%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">31&#x02013;50&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (70%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">32 (56%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (30%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">51&#x02013;70&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (10%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (18%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (40%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;70&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7%)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD duration in years (median, IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">2, (1&#x02013;2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (2&#x02013;10)</td><td align="left" valign="top" rowspan="1" colspan="1">1.9 (1.2&#x02013;1.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (100%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (65%)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (90%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6&#x02013;15&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (17%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (10%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">16&#x02013;25&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">26&#x02013;35&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;35&#x000a0;years (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="clt270038-ntgp-0002"><fn id="clt270038-note-0002"><p>
<italic toggle="yes">Note</italic>: Age, gender and disease duration of SD patients participating in the item generation and reduction phase as well as in the cognitive debriefing interviews for german&#x02010;speaking participants.</p></fn><fn id="clt270038-note-0010"><p>Abbreviation: IQR, Inter Quartile Range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="clt270038-sec-0170"><label>4.2</label><title>Item selection</title><p>In the item selection phase, 46 females and 12 males were included (Table&#x000a0;<xref rid="clt270038-tbl-0002" ref-type="table">2</xref>). Over 50% of the study population were between 31 and 50&#x000a0;years. Around 65% of the patients had a disease duration of 5&#x000a0;years or less. However, almost 20% of the patients reported a disease duration between 6 and 15&#x000a0;years (Table&#x000a0;<xref rid="clt270038-tbl-0002" ref-type="table">2</xref>). Eighty percent of the patients were treated with antihistamines at the time of participation. The results of the impact analysis are shown in Table&#x000a0;<xref rid="clt270038-tbl-0001" ref-type="table">1</xref>. Items were preselected when their impact score was &#x02265;1.5 points (Table&#x000a0;<xref rid="clt270038-tbl-0001" ref-type="table">1</xref>). This cut&#x02010;off value was recommended by the expert group since it allowed distinguishing between relevant and nonrelevant items as well as important and non&#x02010;important items. Further reduction was based on the inter&#x02010;item correlation analysis (Table&#x000a0;<xref rid="clt270038-tbl-0003" ref-type="table">3</xref>), the additional criteria for item deletion and expert review for face validity (Table&#x000a0;<xref rid="clt270038-tbl-0004" ref-type="table">4</xref>). Although, items 15 and 34 had an impact score&#x000a0;&#x0003c;&#x000a0;1.5, the expert group decided to keep them due to their content (face) validity. In addition, items 13 and 15 as well as items 14 and 17 were consolidated into single items to ensure the face validity of the final SD&#x02010;QoL.</p><table-wrap position="float" id="clt270038-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Inter&#x02010;item correlation of items selected by the impact analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Item</th><th align="left" valign="bottom" rowspan="1" colspan="1">1</th><th align="left" valign="bottom" rowspan="1" colspan="1">2</th><th align="left" valign="bottom" rowspan="1" colspan="1">3</th><th align="left" valign="bottom" rowspan="1" colspan="1">13</th><th align="left" valign="bottom" rowspan="1" colspan="1">14</th><th align="left" valign="bottom" rowspan="1" colspan="1">15</th><th align="left" valign="bottom" rowspan="1" colspan="1">16</th><th align="left" valign="bottom" rowspan="1" colspan="1">17</th><th align="left" valign="bottom" rowspan="1" colspan="1">19</th><th align="left" valign="bottom" rowspan="1" colspan="1">22</th><th align="left" valign="bottom" rowspan="1" colspan="1">23</th><th align="left" valign="bottom" rowspan="1" colspan="1">25</th><th align="left" valign="bottom" rowspan="1" colspan="1">34</th><th align="left" valign="bottom" rowspan="1" colspan="1">42</th><th align="left" valign="bottom" rowspan="1" colspan="1">43</th><th align="left" valign="bottom" rowspan="1" colspan="1">58</th><th align="left" valign="bottom" rowspan="1" colspan="1">64</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.66</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.39</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.31</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.80</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.66</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.23</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.41</td><td align="left" valign="top" rowspan="1" colspan="1">0.56</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.28</td><td align="left" valign="top" rowspan="1" colspan="1">0.21</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>13</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.86</td><td align="left" valign="top" rowspan="1" colspan="1">0.69</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.80</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">0.514</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td><td align="left" valign="top" rowspan="1" colspan="1">0.56</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>14</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.86</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.69</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.77</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.72</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.054</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>15</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td><td align="left" valign="top" rowspan="1" colspan="1">0.41</td><td align="left" valign="top" rowspan="1" colspan="1">0.69</td><td align="left" valign="top" rowspan="1" colspan="1">0.69</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.72</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.65</td><td align="left" valign="top" rowspan="1" colspan="1">0.69</td><td align="left" valign="top" rowspan="1" colspan="1">0.36</td><td align="left" valign="top" rowspan="1" colspan="1">0.27</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>16</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.56</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.80</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.77</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.72</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.74</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.70</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.38</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>17</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.74</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.84</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td><td align="left" valign="top" rowspan="1" colspan="1">0.26</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>19</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.65</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.70</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.84</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.34</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>22</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.28</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.72</td><td align="left" valign="top" rowspan="1" colspan="1">0.69</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">0.39</td><td align="left" valign="top" rowspan="1" colspan="1">0.38</td><td align="left" valign="top" rowspan="1" colspan="1">0.41</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>23</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.21</td><td align="left" valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td><td align="left" valign="top" rowspan="1" colspan="1">0.36</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>25</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.39</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.27</td><td align="left" valign="top" rowspan="1" colspan="1">0.38</td><td align="left" valign="top" rowspan="1" colspan="1">0.26</td><td align="left" valign="top" rowspan="1" colspan="1">0.34</td><td align="left" valign="top" rowspan="1" colspan="1">0.39</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.13</td><td align="left" valign="top" rowspan="1" colspan="1">0.34</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>34</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.56</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.38</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.13</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td><td align="left" valign="top" rowspan="1" colspan="1">0.41</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>42</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.31</td><td align="left" valign="top" rowspan="1" colspan="1">0.23</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.41</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td><td align="left" valign="top" rowspan="1" colspan="1">0.34</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.68</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>43</bold>
</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.80</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.66</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>58</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.51</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.41</td><td align="left" valign="top" rowspan="1" colspan="1">0.68</td><td align="left" valign="top" rowspan="1" colspan="1">0.66</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>64</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td><td style="background-color:#D0CECE" align="left" valign="top" rowspan="1" colspan="1">0.71</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot id="clt270038-ntgp-0003"><fn id="clt270038-note-0003"><p>
<italic toggle="yes">Note</italic>: An inter&#x02010;item correlation of preselected items after the impact analysis was performed during the reduction and selection phase Values represent the Spearman's rank correlation coefficient. Spearman's rank correlation coefficients of 0.7&#x02013;0.899 indicate strong and 0.9&#x02013;1 very strong correlations that may be interpreted as a marker of redundancy are highlighted in gray.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="clt270038-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Selection, reduction, or adjustment of items after impact analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">ID</th><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="left" valign="bottom" rowspan="1" colspan="1">Impact score</th><th align="left" valign="bottom" rowspan="1" colspan="1">Missing value (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Floor value (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ceiling value (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Inter&#x02010;item correlations</th><th align="left" valign="bottom" rowspan="1" colspan="1">Expert consensus on selection</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_1</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Itch (intensity)</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>2.9</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>5.3</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**7, **43</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 7 and 43, very low FV and CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_2</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Wheals (intensity)</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>2.5</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>24.6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.8</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>***8</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Redundant to item 8. Low FV and CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_3</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Skin redness (intensity)</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>2.6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>6.9</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>6.9</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**9</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 9. Low FV and CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_7</td><td align="left" valign="top" rowspan="1" colspan="1">Itch (frequency)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.9</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">3.6</td><td align="left" valign="top" rowspan="1" colspan="1">18.1</td><td align="left" valign="top" rowspan="1" colspan="1">**1, **7</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 1. Low FV and CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 1.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_8</td><td align="left" valign="top" rowspan="1" colspan="1">Wheals (frequency)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">26.3</td><td align="left" valign="top" rowspan="1" colspan="1">8.8</td><td align="left" valign="top" rowspan="1" colspan="1">***2</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Redundant to item 2. Low FV and CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 2.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_9</td><td align="left" valign="top" rowspan="1" colspan="1">Skin redness (frequency)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">12.3</td><td align="left" valign="top" rowspan="1" colspan="1">**3</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 3. Low FV and CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 3.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_13</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation at school/study/work</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>2.1</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>29.1</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3.6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**14, **16</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 14 and 16. Low FV and CV. To be included in SD&#x02010;QoL, consolidated with 15</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_14</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on family life</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>1.9</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>29.3</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>6.9</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**13, **16, *17</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 13, 16, 17. Low FV. To be included in SD&#x02010;QoL, consolidated with 17</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_15</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on housework</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>0.9</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>48.3</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**16</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003c;&#x000a0;1.5. Strong correlation with item 16. High FV, low CV. To be included in SD&#x02010;QoL, consolidated with 13.</bold>
</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">
<bold>Item_16</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>Limitation on leisure time</bold>
</td><td rowspan="2" align="char" char="." valign="top" colspan="1">
<bold>1.6</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>27.6</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>1.7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**13, **14,**17</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 13, 14, 17, 19, 20. Low FV and CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**19, **20</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_17</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on partnership</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>1.7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>42.1</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**19, **20, *14, *51</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 14, 19, 20, 51. High FV, low CV. To be included in SD&#x02010;QoL, consolidated with 14</bold>
</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Item_19</td><td rowspan="2" align="left" valign="top" colspan="1">Limitation on sexual life</td><td rowspan="2" align="char" char="." valign="top" colspan="1">1.6</td><td rowspan="2" align="left" valign="top" colspan="1">&#x0003c;5%</td><td rowspan="2" align="left" valign="top" colspan="1">42.1</td><td rowspan="2" align="left" valign="top" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">*13, *14, **16</td><td rowspan="2" align="left" valign="top" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 16, 17, 20. High FV, low CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 16 and 17.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">**17 *20</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Item_20</td><td rowspan="2" align="left" valign="top" colspan="1">Limitation on physical activities</td><td rowspan="2" align="char" char="." valign="top" colspan="1">1.5</td><td rowspan="2" align="left" valign="top" colspan="1">&#x0003c;5%</td><td rowspan="2" align="left" valign="top" colspan="1">31</td><td rowspan="2" align="left" valign="top" colspan="1">1.7</td><td align="left" valign="top" rowspan="1" colspan="1">*13, *14, **16</td><td rowspan="2" align="left" valign="top" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 16, 17. High FV, low CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 16 and 17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">**17, *19, *22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_22</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on body care</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>1.7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>27.6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>5.2</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**14</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 14. Low FV and CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_23</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Limitation on choice of clothes</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>1.5</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>27.6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>5.2</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>*22</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x02265;&#x000a0;1.5. Good correlation with item 22. Low FV and CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_25</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Impairment of sleep</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>1.5</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>46.6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3.4</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**26</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x02265;&#x000a0;1.5. Strong correlation with item 26. High FV, low CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_26</td><td align="left" valign="top" rowspan="1" colspan="1">Unable to fall asleep</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.6</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">51.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.7</td><td align="left" valign="top" rowspan="1" colspan="1">**25</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 25. High FV, low CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 25.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_34</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Appearance</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>1.4</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>36.2</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>5.2</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>*64, *68,</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003c;&#x000a0;1.5. Good correlation with item 64, 68. High FV, low CV. Expert group decision: To include in the SD&#x02010;QoL due to face validity.</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_40</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling of no control over urticaria</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.7</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">31</td><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="left" valign="top" rowspan="1" colspan="1">*42, *43, * 45, **51, **55, **58, **64 *65</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 51, 55, 58, 64. High FV, low CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 64.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_42</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Fear that disease might worsen</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>2.0</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>24,6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>12.3</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>*40, *51, *58, *64</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Good correlation to item 40, 51, 58, 64. Low FV and CV. To be included in SD&#x02010;QoL.</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Item_43</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Scratching frequency</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>3.0</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>29.8</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>*1, *7, *64</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Good correlation to item 1, 7, 64. Low FV and CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_45</td><td align="left" valign="top" rowspan="1" colspan="1">Anxious about drug side &#x02010; effects</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.7</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">44.6</td><td align="left" valign="top" rowspan="1" colspan="1">12.5</td><td align="left" valign="top" rowspan="1" colspan="1">*51, *55, *56, 58*</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Good correlation to 51, 55, 56, 58 items. High FV and low CV. Expert group decision: Not included in the SD&#x02010;QoL due to face validity.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_51</td><td align="left" valign="top" rowspan="1" colspan="1">Emotionally burdened</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.9</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">25.9</td><td align="left" valign="top" rowspan="1" colspan="1">12.1</td><td align="left" valign="top" rowspan="1" colspan="1">*42, **55, **56, ** 58, **65, **64</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 55, 56, 58, 64. Low FV and CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 64.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_55</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling helpless</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.6</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">41.4</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">**51, ***56, **58, **64</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Redundant to 56, strong correlation to item 51, 58, 64. High FV and low CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 64.</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Item_56</td><td rowspan="2" align="left" valign="top" colspan="1">Feeling at the mercy of the disease</td><td rowspan="2" align="char" char="." valign="top" colspan="1">1.6</td><td rowspan="2" align="left" valign="top" colspan="1">&#x0003c;5%</td><td rowspan="2" align="left" valign="top" colspan="1">44.8</td><td rowspan="2" align="left" valign="top" colspan="1">20.7</td><td align="left" valign="top" rowspan="1" colspan="1">**51, ***55</td><td rowspan="2" align="left" valign="top" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Redundant to 55, strong correlation to item 51, 58, 64. High FV and low CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 64.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">**58,**64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_58</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling frustrated</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.9</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">22.8</td><td align="left" valign="top" rowspan="1" colspan="1">17.5</td><td align="left" valign="top" rowspan="1" colspan="1">**51, **55, **64</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 51, 55, 64. Low FV and CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 64.</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">
<bold>Item_64</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>Feeling annoyed</bold>
</td><td rowspan="2" align="char" char="." valign="top" colspan="1">
<bold>2.2</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>&#x0003c;5%</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>21.1</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>24.6</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>*34, **51</bold>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<bold>IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 51, 55, ,58, 65. Low FV and CV. To be included in SD&#x02010;QoL</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**55, **58, **65</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Item_65</td><td align="left" valign="top" rowspan="1" colspan="1">Feeling upset</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">31.6</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>**</bold>64</td><td align="left" valign="top" rowspan="1" colspan="1">IS&#x000a0;&#x0003e;&#x000a0;1.5. Strong correlation with item 64. High FV and CV. Expert group decision: Not included in the SD&#x02010;QoL because of strong correlation and content redundancy (face validity) with item 64.</td></tr></tbody></table><table-wrap-foot id="clt270038-ntgp-0004"><fn id="clt270038-note-0004"><p>
<italic toggle="yes">Note:</italic> Items with impact score&#x000a0;&#x02265;&#x000a0;1.5 were selected, except for items 15 and 34 due to face validity as well as items 19 and 58 due to redundancy and face validity. Items 13 and 15 as well as items 14 and 17 were consolidated into one item due to face validity. Additional items were excluded due to their inter&#x02010;item correlations and/or Visual Analogue Scale/Verbal Rating Scale QoL correlations. Some items with an impact score&#x000a0;&#x0003e;&#x000a0;1.5 were excluded due to very strong and strong inter&#x02010;item correlations (redundancy) (e.g. items 7, 8, 9, 20, 26, 40, 45, 51, 55, 56 and 65). High floor values (&#x02265;30%) of items 20, 26, 40, 45, 55, 56 and 65 were also considered in the selection phase. After the expert panel discussion, a final total number of 13 items were selected for the validation phase. IS (impact score), floor values (FV). Items included in the final SD&#x02010;QoL are depicted in bold.</p></fn><fn id="clt270038-note-0005"><p>*good correlation (0.5&#x02013;0.699), **strong correlation (0.7&#x02013;0.899), ***very strong correlation (&#x02265;0.9).</p></fn></table-wrap-foot></table-wrap><p>In order to confirm that the item selection was valid for both genders, we also performed the impact analysis on females and males separately. Both genders had comparable impact scores, suggesting that there were no major gender differences. However, there was a general tendency that females provided higher relevance scores.</p></sec><sec id="clt270038-sec-0180"><label>4.3</label><title>Final formatting of the symptomatic dermographism quality of life questionnaire and cognitive debriefing</title><p>The item development and item reduction process resulted in a total of 13&#x02010;items. During the final formatting of the SD&#x02010;QoL, an instruction section was added. The final SD&#x02010;QoL instrument is shown in Figure&#x000a0;<xref rid="clt270038-fig-0001" ref-type="fig">1</xref>. In the subsequent cognitive debriefing with 10 SD patients (6 females; median age: 42&#x000a0;years), with a median disease duration of 18&#x000a0;months, no difficulties in understanding the instructions, the single items, or the answer options were reported. In addition, there were no requests for further changes to the questionnaire.</p><fig-group position="float" id="clt270038-fig-0001" content-type="FIGURE"><label>FIGURE 1</label><caption><p>German version of the symptomatic dermographism quality of Life Questionnaire (SD&#x02010;QoL). A final 13&#x02010;item set with instructions and answer options configured as 5&#x02010;point verbal rating scale.</p></caption><fig position="anchor" fig-type="FIGURE" id="d101e3398"><graphic xlink:href="CLT2-15-e70038-g003" position="anchor" id="jats-graphic-1"/></fig><fig position="anchor" fig-type="FIGURE" id="d101e3400"><graphic xlink:href="CLT2-15-e70038-g001" position="anchor" id="jats-graphic-3"/></fig></fig-group></sec><sec id="clt270038-sec-0190"><label>4.4</label><title>Development of an American&#x02010;English version</title><p>In addition to the original German version of the SD&#x02010;QoL, we developed a US American&#x02010;English version (Figure&#x000a0;<xref rid="clt270038-fig-0002" ref-type="fig">2</xref>) as described in the methods section. Cognitive debriefing of the US American&#x02010;English version was performed with 5 US American&#x02010;English native speaking SD patients (3 female, 2 male, median age: 35.6&#x000a0;years) who confirmed that the US American&#x02010;English version is clear to understand.</p><fig-group position="float" id="clt270038-fig-0002" content-type="FIGURE"><label>FIGURE 2</label><caption><p>English version of the symptomatic dermographism quality of Life Questionnaire (SD&#x02010;QoL). A final 13&#x02010;item set with instructions and answer options configured as 5&#x02010;point verbal rating scale.</p></caption><fig position="anchor" fig-type="FIGURE" id="d101e3415"><graphic xlink:href="CLT2-15-e70038-g002" position="anchor" id="jats-graphic-5"/></fig><fig position="anchor" fig-type="FIGURE" id="d101e3417"><graphic xlink:href="CLT2-15-e70038-g004" position="anchor" id="jats-graphic-7"/></fig></fig-group></sec></sec><sec id="clt270038-sec-0200"><label>5</label><title>DISCUSSION</title><p>Symptomatic dermographism is the most common type of CIndU, characterized by a long duration and frequently by a strong impairment in QoL.<xref rid="clt270038-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> QoL scores are important instruments used in the daily clinical care as well as in clinical trials to assess the impact of diseases on patient's performance, physical, emotional and social well&#x02010;being.<xref rid="clt270038-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> As of now, there is no specific tool available to evaluate the QoL in SD patients. Here, we report the development of such an instrument, the first PROM to retrospectively assess the QoL in SD patients, the SD&#x02010;QoL. Validation and reliability of the SD&#x02010;QoL will be conducted in a separate study.</p><p>After the development of a conceptual framework for the SD&#x02010;QoL, 69 potential items were generated using a combined method of patient's interviews, literature search, and expert input. In the subsequent item selection and reduction phase, the results of the impact analysis were the main criterion for item deletion. This ensured that the patient perspective was rated highest in the development process. Additional criteria for item selection included an inter&#x02010;item correlation, missing values, floor and ceiling effects and an expert review for face validity. This combined approach allowed us to select the most important items and reduce the final item set to 13 questions, keeping a low respondent burden.</p><p>Although the final SD&#x02010;QoL covers some similar areas as the Chronic Urticaria QoL Questionnaire (CU&#x02010;Q<sub>2</sub>oL),<xref rid="clt270038-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> the SD&#x02010;QoL does not harbor any item related to the treatment and the recall period was seven instead of 14 days. CU&#x02010;Q<sub>2</sub>oL is a validated PROM; however, it does not assess trigger exposure or avoidance, which is crucial for SD patients' symptom burden and its impact on QoL. Therefore, the CU&#x02010;Q<sub>2</sub>oL is not well suited to assess QoL in SD patients. In addition, comparable QoL scores that also evaluate the impairment of QoL, such as the CU&#x02010;Q2oL,<xref rid="clt270038-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> AE&#x02010;QoL<xref rid="clt270038-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> and CholU&#x02010;QoL<xref rid="clt270038-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, also used a five&#x02010;point Likert scale and were therefore prototypes for the development of the SD&#x02010;QoL.</p><p>Antihistamines are the only licensed treatment for SD as well as other chronic inducible urticarias.<xref rid="clt270038-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> However, many SD patients taking antihistamines do not achieve sufficient control of their symptoms.<xref rid="clt270038-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Moreover, moisturization of the skin can be used to mitigate the itch and reduce the itch&#x02010;scratch cycle. Clinical trials that assess novel therapies for SD patients are needed. For this, validated PROMs that evaluate and compare the response of different therapies in clinical studies are mandatory. SD&#x02010;QoL provides a standardized way to objectively assess patients' disease&#x02010;related QoL impairment in routine clinical care and will be an important instrument in clinical trials. In addition, the SD&#x02010;QoL is easy to fill out during regular outpatient visits, taking approximately less than 5&#x000a0;min to complete.</p><p>The strengths of our study include that SD patients with a broad range of disease durations, disease activities, different ages, both genders and in two independent centers were included in our analysis and that the patients' input was the major source during the SD&#x02010;QoL development. As expected, a large proportion of the study population was female since higher prevalence of females is observed in chronic urticaria. Moreover, SD&#x02010;QoL exhibited high comprehensibility, as demonstrated during the cognitive debriefing. Another strength of this work is that it was accompanied by an experienced expert group with knowledge in the field of SD as well as PROM development.<xref rid="clt270038-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="clt270038-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="clt270038-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="clt270038-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Limitations of our study include: (i) the relatively small sample size, (ii) only adults were included, (iii) since the participating centers were tertiary care centers, a selection bias might be present with participation of strongly affected patients. However, our sample size represents all severity levels from mild, moderate to severe SD cases based on the UCT and the DLQI scores. Nonetheless, the FDA guidance document points out that the number of patients is not as critical as interview quality and patient diversity included in the study.<xref rid="clt270038-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Lastly, content (face) validity review could encounter a certain degree of bias since this process depends on the opinion of the expert working group.</p><p>In conclusion, the final 13&#x02010;item SD&#x02010;QoL is the first PROM to specifically assess QoL in SD patients. Its retrospective approach and user&#x02010;friendliness ensure that it is an easy tool for daily patient care as well as clinical trials. The current ongoing validation study will provide important additional insights into the validity and reliability of the SD&#x02010;QoL in the near future.</p></sec><sec sec-type="COI-statement" id="clt270038-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="clt270038-sec-0210"><title>ACKNOWLEDGMENTS</title><p>We thank all physicians in the outpatient clinic at the Department of Dermatology and Allergology, Charit&#x000e9; &#x02010; Universit&#x000e4;tsmedizin Berlin and at the Department of Dermatology of the University Medical Center in Mainz, Germany for their help in recruiting suitable patients. We thank Ezzat Alarbeed for his support of this study and Beate Schinzel for technical assistance. We thank MOXIE for making the SD&#x02010;QoL available free of charge for non&#x02010;commercial purposes including academic research and patient care (<ext-link xlink:href="http://www.moxie-gmbh.de/" ext-link-type="uri">www.moxie&#x02010;gmbh.de</ext-link>). We also want to thank all our patients who supported this study. Open Access funding enabled and organized by Projekt DEAL.</p></ack><sec sec-type="data-availability" id="clt270038-sec-0240"><title>DATA AVAILABILITY STATEMENT</title><p>Data available on request from the authors.</p></sec><ref-list content-type="cited-references" id="clt270038-bibl-0001"><title>REFERENCES</title><ref id="clt270038-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="clt270038-cit-0001">
<string-name>
<surname>Schoepke</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>M&#x00142;ynek</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Weller</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Church</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maurer</surname>
<given-names>M</given-names>
</string-name>. <article-title>Symptomatic dermographism: an inadequately described disease</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2015</year>;<volume>29</volume>(<issue>4</issue>):<fpage>708</fpage>&#x02010;<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1111/jdv.12661</pub-id>
<pub-id pub-id-type="pmid">25174372</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="clt270038-cit-0002">
<string-name>
<surname>Magerl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Altrichter</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Borzova</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>The definition, diagnostic testing, and management of chronic inducible urticarias &#x02010; The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision</article-title>. <source>Allergy</source>. <year>2016</year>;<volume>71</volume>(<issue>6</issue>):<fpage>780</fpage>&#x02010;<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1111/all.12884</pub-id>
<pub-id pub-id-type="pmid">26991006</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="clt270038-cit-0003">
<string-name>
<surname>Taskapan</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Harmanyeri</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Evaluation of patients with symptomatic dermographism</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2006</year>;<volume>20</volume>(<issue>1</issue>):<fpage>58</fpage>&#x02010;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-3083.2005.01372.x</pub-id>
<pub-id pub-id-type="pmid">16405609</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="clt270038-cit-0004">
<string-name>
<surname>Jedele</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Michels</surname>
<given-names>VV</given-names>
</string-name>. <article-title>Familial dermographism</article-title>. <source>Am J Med Genet</source>. <year>1991</year>;<volume>39</volume>(<issue>2</issue>):<fpage>201</fpage>&#x02010;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.1320390216</pub-id>
<pub-id pub-id-type="pmid">2063925</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="clt270038-cit-0005">
<string-name>
<surname>Salazar Villa</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Acosta Ortiz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mejia Ortega</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>[Symptomatic dermatographism and HLA antigens]</article-title>. <source>Rev Alerg</source>. <year>1992</year>;<volume>39</volume>(<issue>5</issue>):<fpage>89</fpage>&#x02010;<lpage>95</lpage>.<pub-id pub-id-type="pmid">1462107</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="clt270038-cit-0006">
<string-name>
<surname>Kulthanan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ungprasert</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tuchinda</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Symptomatic dermographism: a systematic review of treatment options</article-title>. <source>J Allergy Clin Immunol Pract</source>. <year>2020</year>;<volume>8</volume>(<issue>9</issue>):<fpage>3141</fpage>&#x02010;<lpage>3161</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaip.2020.05.016</pub-id>
<pub-id pub-id-type="pmid">32473421</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="clt270038-cit-0007">
<string-name>
<surname>Kolkhir</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gim&#x000e9;nez&#x02010;Arnau</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Kulthanan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Peter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Metz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maurer</surname>
<given-names>M</given-names>
</string-name>. <article-title>Urticaria</article-title>. <source>Nat Rev Dis Prim</source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>61</fpage>. <pub-id pub-id-type="doi">10.1038/s41572-022-00389-z</pub-id>
<pub-id pub-id-type="pmid">36109590</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="clt270038-cit-0008">
<string-name>
<surname>Kaplan</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Garofalo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sigler</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hauber</surname>
<given-names>T</given-names>
</string-name>. <article-title>Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies</article-title>. <source>N Engl J Med</source>. <year>1981</year>;<volume>305</volume>(<issue>18</issue>):<fpage>1074</fpage>&#x02010;<lpage>1077</lpage>. <pub-id pub-id-type="doi">10.1056/nejm198110293051808</pub-id>
<pub-id pub-id-type="pmid">6168912</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="clt270038-cit-0009">
<string-name>
<surname>Murphy</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Zollman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Greaves</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Winkelmann</surname>
<given-names>R</given-names>
</string-name>. <article-title>Symptomatic dermographism (factitious urticaria)&#x02010;&#x02010;passive transfer experiments from human to monkey</article-title>. <source>Br J Dermatol</source>. <year>1987</year>;<volume>116</volume>(<issue>6</issue>):<fpage>801</fpage>&#x02010;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.1987.tb04898.x</pub-id>
<pub-id pub-id-type="pmid">3620341</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="clt270038-cit-0010">
<string-name>
<surname>Newcomb</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>H</given-names>
</string-name>. <article-title>Dermographia mediated by immunoglobulin E</article-title>. <source>Am J Med</source>. <year>1973</year>;<volume>54</volume>(<issue>2</issue>):<fpage>174</fpage>&#x02010;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1016/0002-9343(73)90221-0</pub-id>
<pub-id pub-id-type="pmid">4631173</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="clt270038-cit-0011">
<string-name>
<surname>Kaplan</surname>
<given-names>AP</given-names>
</string-name>. <article-title>The pathogenic basis of urticaria and angioedema: recent advances</article-title>. <source>Am J Med</source>. <year>1981</year>;<volume>70</volume>(<issue>4</issue>):<fpage>755</fpage>&#x02010;<lpage>758</lpage>. <pub-id pub-id-type="doi">10.1016/0002-9343(81)90528-3</pub-id>
<pub-id pub-id-type="pmid">7211911</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="clt270038-cit-0012">
<string-name>
<surname>Maurer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Metz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brehler</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence</article-title>. <source>J Allergy Clin Immunol</source>. <year>2018</year>;<volume>141</volume>(<issue>2</issue>):<fpage>638</fpage>&#x02010;<lpage>649</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2017.06.032</pub-id>
<pub-id pub-id-type="pmid">28751232</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="clt270038-cit-0013">
<string-name>
<surname>Terhorst&#x02010;Molawi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hawro</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Grekowitz</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Anti&#x02010;KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria</article-title>. <source>Allergy</source>. <year>2023</year>;<volume>78</volume>(<issue>5</issue>):<fpage>1269</fpage>&#x02010;<lpage>1279</lpage>. <pub-id pub-id-type="doi">10.1111/all.15585</pub-id>
<pub-id pub-id-type="pmid">36385701</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="clt270038-cit-0014">
<string-name>
<surname>Zuberbier</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Abdul Latiff</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Abuzakouk</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria</article-title>. <source>Allergy</source>. <year>2022</year>;<volume>77</volume>(<issue>3</issue>):<fpage>734</fpage>&#x02010;<lpage>766</lpage>. <pub-id pub-id-type="doi">10.1111/all.15090</pub-id>
<pub-id pub-id-type="pmid">34536239</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="clt270038-cit-0015">
<string-name>
<surname>Baiardini</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Braido</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fassio</surname>
<given-names>O</given-names>
</string-name>, et&#x000a0;al. <article-title>A new tool to assess and monitor the burden of chronic cough on quality of life: chronic Cough Impact Questionnaire</article-title>. <source>Allergy</source>. <year>2005</year>;<volume>60</volume>(<issue>4</issue>):<fpage>482</fpage>&#x02010;<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1111/j.1398-9995.2005.00743.x</pub-id>
<pub-id pub-id-type="pmid">15727580</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="clt270038-cit-0016">
<string-name>
<surname>Wallengren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Isaksson</surname>
<given-names>A</given-names>
</string-name>. <article-title>Urticarial dermographism: clinical features and response to psychosocial stress</article-title>. <source>Acta Derm Venereol</source>. <year>2007</year>;<volume>87</volume>(<issue>6</issue>):<fpage>493</fpage>&#x02010;<lpage>498</lpage>. <pub-id pub-id-type="doi">10.2340/00015555-0306</pub-id>
<pub-id pub-id-type="pmid">17989886</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="clt270038-cit-0017">
<string-name>
<surname>Ruft</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Asady</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Staubach</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Development and validation of the cholinergic urticaria quality&#x02010;of&#x02010;life questionnaire (CholU&#x02010;QoL)</article-title>. <source>Clin Exp Allergy</source>. <year>2018</year>;<volume>48</volume>(<issue>4</issue>):<fpage>433</fpage>&#x02010;<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1111/cea.13102</pub-id>
<pub-id pub-id-type="pmid">29369455</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="clt270038-cit-0018">
<string-name>
<surname>Bottomley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Claassens</surname>
<given-names>L</given-names>
</string-name>. <article-title>Patient&#x02010;reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency</article-title>. <source>Eur J Cancer</source>. <year>2009</year>;<volume>45</volume>(<issue>3</issue>):<fpage>347</fpage>&#x02010;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2008.09.032</pub-id>
<pub-id pub-id-type="pmid">19013787</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="clt270038-cit-0019">
<string-name>
<surname>Health</surname>
<given-names>USDo</given-names>
</string-name>, <collab collab-type="authors">U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health</collab>
. <article-title>Guidance for industry: patient&#x02010;reported outcome measures: use in medical product development to support labeling claims: draft guidance</article-title>. <source>Health Qual Life Outcome</source>. <year>2006</year>;<volume>4</volume>(<issue>1</issue>):<elocation-id>79</elocation-id>. <pub-id pub-id-type="doi">10.1186/1477-7525-4-79</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="clt270038-cit-0020">
<string-name>
<surname>Baiardini</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bousquet</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Brzoza</surname>
<given-names>Z</given-names>
</string-name>, et&#x000a0;al. <article-title>Recommendations for assessing patient&#x02010;reported outcomes and health&#x02010;related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper</article-title>. <source>Allergy</source>. <year>2010</year>;<volume>65</volume>(<issue>3</issue>):<fpage>290</fpage>&#x02010;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1111/j.1398-9995.2009.02263.x</pub-id>
<pub-id pub-id-type="pmid">19930232</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="clt270038-cit-0021">
<string-name>
<surname>Burckhardt</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>KL</given-names>
</string-name>. <article-title>The Quality of Life Scale (QOLS): reliability, validity, and utilization</article-title>. <source>Health Qual Life Outcome</source>. <year>2003</year>;<volume>1</volume>:<elocation-id>60</elocation-id>. <pub-id pub-id-type="doi">10.1186/1477-7525-1-60</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="clt270038-cit-0022">
<string-name>
<surname>Weller</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Groffik</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Church</surname>
<given-names>MK</given-names>
</string-name>, et&#x000a0;al. <article-title>Development and validation of the Urticaria Control Test: a patient&#x02010;reported outcome instrument for assessing urticaria control</article-title>. <source>J Allergy Clin Immunol</source>. <year>2014</year>;<volume>133</volume>(<issue>5</issue>):<fpage>1365</fpage>&#x02010;<lpage>1372</lpage>. 1372 e1&#x02010;6. <pub-id pub-id-type="doi">10.1016/j.jaci.2013.12.1076</pub-id>
<pub-id pub-id-type="pmid">24522090</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="clt270038-cit-0023">
<string-name>
<surname>Siebenhaar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>von Tschirnhaus</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Development and validation of the mastocytosis quality of life questionnaire: MC&#x02010;QoL</article-title>. <source>Allergy</source>. <year>2016</year>;<volume>71</volume>(<issue>6</issue>):<fpage>869</fpage>&#x02010;<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1111/all.12842</pub-id>
<pub-id pub-id-type="pmid">26797792</pub-id>
</mixed-citation></ref><ref id="clt270038-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="clt270038-cit-0024">
<string-name>
<surname>Weller</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Groffik</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Magerl</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Development and construct validation of the angioedema quality of life questionnaire</article-title>. <source>Allergy</source>. <year>2012</year>;<volume>67</volume>(<issue>10</issue>):<fpage>1289</fpage>&#x02010;<lpage>1298</lpage>. <pub-id pub-id-type="doi">10.1111/all.12007</pub-id>
<pub-id pub-id-type="pmid">22913638</pub-id>
</mixed-citation></ref></ref-list></back></article>